amitriptyline has been researched along with Torsade de Pointes in 6 studies
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.
amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amitriptyline was involved in 37 859 (78." | 1.33 | Frequency of high-risk use of QT-prolonging medications. ( Allen LaPointe, NM; Chan, KA; Curtis, LH; Gurwitz, JH; Kramer, JM; Lafata, JE; Platt, R; Raebel, MA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Mirams, GR | 1 |
| Cui, Y | 1 |
| Sher, A | 1 |
| Fink, M | 1 |
| Cooper, J | 1 |
| Heath, BM | 1 |
| McMahon, NC | 1 |
| Gavaghan, DJ | 1 |
| Noble, D | 1 |
| Wiśniowska, B | 1 |
| Mendyk, A | 1 |
| Fijorek, K | 1 |
| Glinka, A | 1 |
| Polak, S | 1 |
| Ryan, K | 1 |
| Benz, P | 1 |
| Zosel, A | 1 |
| Farkas, A | 1 |
| Theobald, J | 1 |
| Curtis, LH | 2 |
| Østbye, T | 1 |
| Sendersky, V | 1 |
| Hutchison, S | 1 |
| Allen LaPointe, NM | 2 |
| Al-Khatib, SM | 1 |
| Usdin Yasuda, S | 1 |
| Dans, PE | 1 |
| Wright, A | 1 |
| Califf, RM | 1 |
| Woosley, RL | 1 |
| Schulman, KA | 1 |
| Chan, KA | 1 |
| Kramer, JM | 1 |
| Lafata, JE | 1 |
| Gurwitz, JH | 1 |
| Raebel, MA | 1 |
| Platt, R | 1 |
| Dorsey, ST | 1 |
| Biblo, LA | 1 |
6 other studies available for amitriptyline and Torsade de Pointes
| Article | Year |
|---|---|
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; | 2011 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computationa | 2012 |
QTc Prolongation in Poison Center Exposures to CredibleMeds List of Substances with "Known Risk of Torsades de Pointes".
Topics: Amitriptyline; Arrhythmias, Cardiac; Diphenhydramine; Electrocardiography; Flecainide; Humans; Long | 2022 |
Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients.
Topics: Adult; Aged; Amitriptyline; Anti-Bacterial Agents; Anti-Infective Agents; Antidepressive Agents, Sec | 2003 |
Frequency of high-risk use of QT-prolonging medications.
Topics: Age Factors; Aged; Amitriptyline; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Antidepressive Agen | 2006 |
Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Antifungal Agents; Drug Interactions; Electrocardio | 2000 |